vixotrigine vixotrigine vixotrigine (inn, usan), formerly known as raxatrigine (inn, usan), is an analgesic which is under development by convergence pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (tgn). vixotrigine was originally claimed to be a selective central nav1.3 blocker, but was subsequently redefined as a selective peripheral nav1.7 blocker. following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. as of january 2018, it is in phase iii clinical trials for trigeminal neuralgia and is in phase ii clinical studies for erythromelalgia and neuropathic pain. it was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued. vixotrigineclinical dataother namesraxatrigine; cnv1014802; gsk-1014802; biib 074routes ofadministrationby mouthatc codenoneidentifiers iupac name (2s,5r)-5-phenyl]pyrrolidine-2-carboxamide cas number934240-30-9 934240-35-4 (mesylate)pubchem cid16046068chemspider13174481uniiqqs4j85k6ykeggd11179chemical and physical dataformulac18h19fn2o2molar mass314.360 g·mol−13d model (jsmol)interactive image smiles c1cc(nc1c2=cc=c(c=c2)occ3=cc=cc=c3f)c(=o)n inchi inchi=1s/c18h19fn2o2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21h,9-11h2,(h2,20,22)/t16-,17+/m1/s1key:jescetifnofkeu-sjorkvtesa-n